The overarching goals of the Tumor Immunology Training Program (TITP) at the Roswell Park Cancer Institute (RPCI) Graduate Division are to educate, train and prepare talented pre-doctoral students for a profession in cancer immunology research. Driven by significant advances in understanding how the immune system can be weaponized against cancer, future leaders in tumor immunology will not only be well-trained in the discipline, but also will have a strong appreciation of the potential translational impact to human cancer biology and therapy. The unique, cancer-focus within the TITP introduces trainees to an advanced didactic and conceptual cancer immunology educational paradigm that encapsulates knowledge spanning the continuum of basic science to clinical application. The uniqueness of this TITP is further enhanced by the integration of an academic environment comprised of diverse faculty concentrated within a prestigious NCI-designated Comprehensive Cancer Center. Trainees are exposed to a comprehensive portfolio of cancer-related topics that will be enhanced through a new ?umbrella? academic curriculum starting in the fall of 2018. It is during the first year of study when trainees will select the tumor immunology-specific ?track? and then conduct their doctoral research with TITP faculty with expertise in basic, translational, or clinical sciences. The primary mission of the training grant renewal is to support competitively selected students during their third and fourth years of study. The funds requested cover stipends and tuition for 4 pre-doctoral students per year. This funding is crucial to continue the upward trajectory experienced for nearly 15 years of NRSA support in the quality and diversity of pre-doctoral trainees focused on complex and challenging immunologic questions in cancer. NRSA-supported trainees are prepared for a competitive biomedical career through didactic lectures and concept-driven learning in tumor immunology and biology, grant writing and ethical conduct of research. After completing all formal course work, degree conferral is dependent upon passing the preliminary exam, fulfilling a first-authored publication requirement, and passing the dissertation defense reflecting the novel and original findings of the student's body-of-work. Trainees who complete this TITP will be well-versed in all major facets of tumor immunology and will have the solid foundation upon which to build cancer-focused careers, guided by a clear vision of its impact on human cancer biology and treatment.

Public Health Relevance

The incidence of neoplasia and death resulting from this disease remains a significant public health challenge globally, and it has become increasingly evident that immune-based approaches will have a substantial impact in our understanding of cancer prevention, diagnosis, prognosis, and treatment. Pre-doctoral training provided by the Tumor Immunology Training Program (TITP) is directly pertinent to public health. The continued primary mission of the TITP is to educate, train and prepare the next generation of talented scientists with the concepts, knowledge and skills of fundamental and translational tumor immunology, which provides the necessary foundation to develop and advance innovative approaches to human cancer biology and therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA085183-17
Application #
9769624
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
2019-09-01
Project End
2023-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
17
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Burkard-Mandel, Lauren; O'Neill, Rachel; Colligan, Sean et al. (2018) Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. Oncoimmunology 7:e1419115
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Bucsek, Mark J; Giridharan, Thejaswini; MacDonald, Cameron R et al. (2018) An overview of the role of sympathetic regulation of immune responses in infectious disease and autoimmunity. Int J Hyperthermia 34:135-143
Bianchi-Smiraglia, Anna; Bagati, Archis; Fink, Emily E et al. (2018) Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. J Clin Invest 128:4682-4696
Sass, Stephanie N; Ramsey, Kimberley D; Egan, Shawn M et al. (2018) Tumor-associated myeloid cells promote tumorigenesis of non-tumorigenic human and murine prostatic epithelial cell lines. Cancer Immunol Immunother 67:873-883
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Bucsek, Mark J; Qiao, Guanxi; MacDonald, Cameron R et al. (2017) ?-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res 77:5639-5651
Egan, Shawn M; Karasik, Ellen; Ellis, Leigh et al. (2017) miR-30e* is overexpressed in prostate cancer and promotes NF-?B-mediated proliferation and tumor growth. Oncotarget 8:67626-67638
Szender, J Brian; Emmons, Tiffany; Belliotti, Sarah et al. (2017) Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol 146:491-497
Leigh, Nicholas D; O'Neill, Rachel E; Du, Wei et al. (2017) Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. J Immunol 199:336-347

Showing the most recent 10 out of 60 publications